A pooled analysis, which included three Phase III randomized controlled trials that compared the efficacy of erlotinib with other therapies in EGFR-wild type (EGFR-wt) NSCLC patients, also suggested a significant benefit of erlotinib treatment [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.